GlassScriptPhysician profile
Kelsey Johnson
NPI 1407577745
$5,975.12
in general payments reported to CMS, 2019-2025
16 companies · $4,794 in 2025
The $4,794 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $612 · 2024: $568 · 2025: $4,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570 · Honoraria: $2,000 · Travel and Lodging: $223 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,569.58 |
| Honoraria | $2,000.00 |
| Travel and Lodging | $223.16 |
| Education | $182.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $2,531.80 | 2025 | Sucraid |
| Abbvie INC. | $1,527.31 | 2023-2025 | |
| Janssen Biotech, INC. | $443.48 | 2024-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $408.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $286.65 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $159.81 | 2023 | Rebyota |
| Lilly USA, LLC | $142.40 | 2025 | Omvoh |
| Genzyme Corporation | $138.16 | 2024 | |
| Ardelyx, INC. | $87.40 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $58.65 | 2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $46.89 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $40.90 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.36 | 2023 | Xifaxan, Trulance |
| Pfizer INC. | $30.40 | 2024 | |
| Organon LLC | $22.05 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $16.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.